Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 294R |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Testosterone supplemented |
| Graft Site | Renal |
| Current Generation (* indicates number of generations grown in Castrate host) |
7 |
| Average PDX Generation Time (days +/- SEM) | 188 ± 45 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 294R |
|---|---|
| AR | Y |
| PSA | Y |
| PSMA | Y |
| NE | N |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 294R | FANCD2 | -0.827 | 1.127 | Loss | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 294R | PTEN | -0.994 | 1.004 | Loss | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 294R | SUFU | -0.994 | 1.004 | Loss | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 294R | BRCA2 | -0.828 | 1.126 | Loss | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 294R | RB1 | -0.765 | 1.177 | Loss | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 294R | SMAD2 | -0.762 | 1.179 | Loss | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 294R | BRAF | 0.660 | 3.160 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 294R | EZH2 | 0.660 | 3.160 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
| 294R | KMT2C | 0.660 | 3.160 | Gain | MURAL Prostate Cancer PDX collection | Targeted GARVAN Panel | hg19 |
Clinical Information
| Sample Number | 294R |
|---|---|
| Sample Site | Prostate |
| Sample source | Radical prostatectomy |
| Pathology Tumour Diagnosis | Adenocarcinoma |
| Gleason Score | 9 |
| Primary Gleason Score | 5 |
| Secondary Gleason Score | 4 |
| Tertiary Gleason Score | None |
| ISUP Grade Group | 5 |
| Tumour Grade | PT3bN0 |
| D'Amico Risk Classification | 7 |
| Tumour Volume (in cc) | 30.2 |
| Treatment Prior to Specimen Collection | None |
Patient Information
| Patient Number | 294 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | 5.6 |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 294R |
| Patient Age (binned in 5 year age groups) | 60-64 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 294R | SUFU | 248 | 0.95 | Missense variant | '7/12 | 0.0002356 | 23.1 | Conflicting interpretations of pathogenicity | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 294R | BRCA2 | 336 | 0.95 | Frameshift variant | '11/28 | 0.0002723 | . | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 294R | EP300 | 362 | 0.71 | Missense variant | '10/31 | 4.06E-06 | 23.6 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 294R | LRP1B | 471 | 0.65 | Missense variant | '44/91 | . | 29.3 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 294R | FGF3 | 450 | 0.46 | Missense variant | '2/3 | . | 27.2 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 294R | MYC | 689 | 0.46 | Missense variant | '3/3 | 7.31E-05 | 24.2 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 294R | JPH2 | 45 | 0.36 | Missense variant | '2/6 | 0.0006877 | 16.43 | Conflicting interpretations of pathogenicity | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 294R | ATM | 436 | 0.32 | Missense variant,splice region variant | '57/63 | . | 32 | Uncertain significance | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 294R | UGT1A5 | 437 | 0.3 | Missense variant | '5/5 | . | 26.9 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 294R | UGT1A4 | 437 | 0.3 | Missense variant | '5/5 | . | 26.9 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 294R | UGT1A9 | 437 | 0.3 | Missense variant | '5/5 | . | 26.9 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 294R | UGT1A7 | 437 | 0.3 | Missense variant | '5/5 | . | 26.9 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
| 294R | UGT1A10 | 437 | 0.3 | Missense variant | '5/5 | . | 26.9 | - | Targeted GARVAN Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | Illumina HiSeq 2500 |
No information in Drug dosing Table